Amyotrophe Lateralsklerose

Zusammenfassung

Das Bild der Amyotrophen Lateralsklerose (ALS) hat sich in den vergangenen Jahren durch neue Erkenntnisse im Hinblick auf Phänotyp und Verlauf, Neuropathologie und Genetik deutlich gewandelt. Zudem werden aktuell innovative verlaufsmodifizierende Therapieansätzen sichtbar.

• Literatur

• 1 Brettschneider J, Del Tredici K, Toledo JB. et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013; 74: 20-38
• 2 Weishaupt JH, Hyman T, Dikic I. Common Molecular Pathways in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Trends Mol Med 2016; 22: 769-783
• 3 Brettschneider J, Del Tredici K, Irwin DJ. et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol 2014; 127: 423-439
• 4 Feiler MS, Strobel B, Freischmidt A. et al. TDP-43 is intercellularly transmitted across axon terminals. J Cell Biol 2015; 211: 897-911
• 5 Ludolph A 1, Drory V, Hardiman O. et al. WFN Research Group On ALS/MND. A revision of the El Escorial criteria – 2015. Amyotroph Lateral Scler Frontotemporal Degener 2015; 16: 291-292
• 6 Braak H, Brettschneider J, Ludolph AC. et al. Amyotrophic lateral sclerosis – a model of corticofugal axonal spread. Nat Rev Neurol 2013; 9: 708-714
• 7 Rosenbohm A, Liu M, Nagel G. et al. Phenotypic differences of amyotrophic lateral sclerosis (ALS) in China and Germany. J Neurol 2018; 265: 774-782
• 8 Spencer PS, Palmer VS, Ludolph AC. On the decline and etiology of high-incidence motor system disease in West Papua (southwest New Guinea). Mov Disord 2005; 20 (Suppl. 12) S119-S126
• 9 Weydt P, Oeckl P, Huss A. et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol 2016; 79: 152-158
• 10 Freischmidt A, Müller K, Zondler L. et al. Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain 2014; 137: 2938-2950
• 11 Brenner D, Yilmaz R, Müller K. et al. Hot-spot KIF5A mutations cause familial ALS. Brain. 12.01.2018 [Epub ahead of print]
• 12 Edaravone Writing group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017; 16: 505-512